Citigroup Inc Verastem, Inc. Transaction History

Citigroup Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	BUY	$0.92 - $11.16 $30,749 - $373,000	33,423 Added 343.54%	43,152 $37,000
Q2 2022 Aug 10, 2022	SELL	$1.02 - $1.83 $450 - $808	-442 Reduced 4.35%	9,729 $12,000
Q1 2022 May 12, 2022	SELL	$1.06 - $2.1 $483,710 - $958,295	-456,331 Reduced 97.82%	10,171 $14,000
Q4 2021 Feb 10, 2022	BUY	$2.05 - $3.2 $348,827 - $544,512	170,160 Added 57.42%	466,502 $956,000
Q3 2021 Nov 10, 2021	BUY	$2.54 - $4.07 $752,708 - $1.21 Million	296,342 New	296,342 $913,000

297K

Ticker VSTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 210,000,000
Market Cap $1.09B
Description
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylat...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.